Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Tubulin C-terminal tail (CTT)-Voltage-dependent anion channel (VDAC) interface represents a critical regulatory checkpoint in cellular bioenergetics and metabolic signaling. Tubulin CTTs are intrinsically disordered, negatively charged regions that project from the microtubule surface or free tubulin dimers and physically interact with VDAC on the outer mitochondrial membrane (Rostovtseva & Bezrukov, 2008). This interaction results in a reversible blockade of the VDAC pore, significantly reducing the conductance of ATP, ADP, and other respiratory metabolites between the mitochondria and the cytoplasm (Gurnev et al., 2011). Beyond VDAC, tubulin CTTs also serve as docking sites for various glycolytic and metabolic enzymes, such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and lactate dehydrogenase (LDH), thereby modulating their enzymatic activity and spatial organization within the cell (Monge et al., 2008). In malignant cells, the high concentration of free dimeric tubulin leads to persistent VDAC closure, which suppresses mitochondrial oxidative phosphorylation and promotes the Warburg effect (Maldonado et al., 2013). Conversely, in neurodegenerative diseases, alterations in tubulin post-translational modifications can disrupt this interface, contributing to mitochondrial dysfunction and energy failure. Therapeutic targeting of this interface, using small molecules like erastin or specific mimetic peptides, offers a novel approach to reprogram cancer metabolism or protect neuronal health by modulating mitochondrial metabolite flux.
Modulation of the physical blockade of the VDAC pore by tubulin C-terminal tails to regulate mitochondrial metabolite flux and membrane potential.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tubulin C-terminal tail-Voltage-dependent anion channel interface (Tubulin-VDAC interface) (Tubulin-VDAC interface).